| Literature DB >> 26394837 |
Trine Pagh Ludvigsen1,2, Rikke Kaae Kirk3, Berit Østergaard Christoffersen4, Henrik Duelund Pedersen5, Torben Martinussen6, Jonas Kildegaard7, Peter M H Heegaard8, Jens Lykkesfeldt9, Lisbeth Høier Olsen10.
Abstract
BACKGROUND: From a pharmacological perspective, readily-available, well-characterized animal models of cardiovascular disease, including relevant in vivo markers of atherosclerosis are important for evaluation of novel drug candidates. Furthermore, considering the impact of diabetes mellitus on atherosclerosis in human patients, inclusion of this disease aspect in the characterization of a such model, is highly relevant. The objective of this study was to evaluate the effect of mild streptozotocin-induced diabetes on ex- and in vivo end-points in a diet-induced atherosclerotic minipig model.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26394837 PMCID: PMC4580291 DOI: 10.1186/s12967-015-0670-2
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Background characteristics of animals in the study
| Group | CD | HFD | HFD-DA | HFD-DB | ||
|---|---|---|---|---|---|---|
| Study duration | 22 weeks (n = 6) | 43 weeks (n = 6) | 22 weeks (n = 6) | 43 weeks (n = 5) | 43 weeks (n = 6) | 43 weeks (n = 5) |
| Body weight (kg) | 15.8 (12.8–17.5) | 24.0 (23.1–24.5) | 23.8 (22.8–25.4) | 53.5 (50.7–60.1) | 52.5 (48.4–53.4) | 56.6 (54.3–58.3) |
| Body fat/body weight (%) | 10.4 (8.5–12.8) | 17.9 (15.6–19.7) | 28.3 (27.8–29.6) | 49.3 (47.3–51.5) | 50.3 (48.6–50.8) | 51.3 (49.0-51.7) |
Median and interquartile range (25th–75th)
CD control animals, HFD high-fat/high-cholesterol fed animals, HFD-D and high-fat/high-cholesterol fed diabetic animals group A and B
Fig. 1Illustration of plasma glucose (a) and fructosamine (b) over time in non-diabetic animals [lean control (CD) and high-fat/high-cholesterol fed (HFD)] compared to the two diabetic groups (HFD-DA, HFD-DB). Diabetes was induced twice in HFD-DA; after 5 and 17 diet-feeding weeks and once in HFD-DB, after 26 diet-feeding weeks. Diabetes induction is illustrated by ticks at each time point, marked by A and B, respectively. Data is shown as mean ± SEM. Please note, not all animals are represented at each time point
Group differences of circulating lipid and glucose markers
| Group | CD | HFD | HFD-DA | HFD-DB | Overall p value | ||
|---|---|---|---|---|---|---|---|
| Study duration | 22 weeks (n = 6) | 43 weeks (n = 6) | 22 weeks (n = 6) | 43 weeks (n = 5) | 43 weeks (n = 6) | 43 weeks (n = 5) | |
| GLUa (mmol/L) | 5.6A (5.3–5.9) | 3.9A (3.6–4.1) | 6.2A (4.9–6.4) | 4.0A (3.9–4.1) | 14.4B (9.4–15.2) | 8.0C (6.1–8.3) | <0.0001 |
| FRAb (µmol/L) | 257A (251–269) | 226A (210–237) | 251A (229–266) | 242A (234–252) | 410B (298–444) | 340C (322–387) | 0.0004 |
| KGa,c (min−1) | 4.5AB (3.2–5.1) | 5.2A (4.9–6.3) | 2.8AB (2.4–3.2) | 3.4AB (2.4–5.3) | 1.2C (0.4–1.8) | 1.4BC (1.1–1.5) | <0.0001 |
| AUCinsulinc (pM min) | 4299A (3173–7746) | 6943A (6356–7399) | 5194A (3676–6236) | 11,506B (10,503–12,714) | 1992A (1669–4937) | 4244A (3368–6747) | 0.0003 |
| TG (mmol/L) | 0.43A (0.35–0.50) | 0.34A (0.29–0.54) | 1.09B (1.03–1.36) | 1.26B (0.75–2.13) | 1.42B (1.26–2.65) | 0.92C (0.9–1.45) | 0.008 |
| TCa (mmol/L) | 1.77A (1.46–2.05) | 1.85A (1.53–2.44) | 21.70B (19.93–26.76) | 16.95B (11.64–25.87) | 19.53B (16.59–22.56) | 18.87B (17.64–19.18) | <0.0001 |
| VLDLb (mmol/L) | 0.07A (0.04–0.10) | 0.14A (0.05–0.69) | 13.66B (9.49–14.62) | 12.50B (7.60–22.32) | 12.30B (10.35–14.19) | 10.25B (9.58–11.58) | <0.0001 |
| LDLa (mmol/L) | 0.72A (0.51–0.85) | 0.67A (0.64–1.31) | 6.72B (5.12–10.68) | 6.22B (4.05–6.57) | 5.42B (4.16–6.33) | 6.21B (6.01–6.43) | <0.0001 |
| HDLa (mmol/L) | 1.00A (0.89–1.11) | 0.82A (0.23–1.06) | 2.96B (2.60–3.41) | 1.26B (1.17–1.38) | 1.16B (0.97–1.56) | 2.05B (1.45–2.19) | <0.0001 |
Median and interquartile range (25th–75th)
Values sharing the same superscript letter are not statistically different. A p value <0.05 is considered significant
CD control animals, HFD high-fat/high-cholesterol fed animals, HFD-D and high-fat/high-cholesterol fed diabetic animals group A and B, respectively, GLU glucose, FRA fructosamine, K intravenous glucose tolerance index, AUC area under the curve of insulin, TG triglycerides, TC total cholesterol, VLDL very-low density lipoprotein, LDL low-density lipoprotein, HDL high-density lipoprotein
aLog-transformed data
bNon-parametric data evaluated in Kruskal–Wallis test
cN = 3 (HFD-D) were excluded due to catheter failure for the intravenous glucose tolerance test (IVGTT)
Fig. 2Plaque burden in lean control (CD), high-fat/high-cholesterol fed [HFD (one outlier removed for CPA and Ratio at 43 diet-weeks)] and high-fat/high-cholesterol fed and diabetic animals (HFD-DA, HFD-DB). a Coronary plaque area (CPA), in left anterior descending artery (LAD), b intima/media-ratio (Ratio) in LAD, c aortic plaque area evaluated en face (APA). Median and interquartile range (25th–75th). P value <0.05 was considered significant. ***p value <0.001
Fig. 3Inflammatory markers in lean control (CD, n = 12), high-fat/high-cholesterol fed (HFD, n = 11) and high-fat/high-cholesterol fed and diabetic animals (HFD-DA, n = 6; HFD-DB, n = 5). a C-reactive protein (CRP), b plasminogen activator inhibitor-1 (PAI-1) (only evaluated after 37 diet-weeks), c oxidized low-density lipoprotein (oxLDL). Median and interquartile range (25th–75th). Please note, part of data from a has been presented in other context [24]. P value <0.05 was considered significant.**p value <0.01, ***p value <0.001
Fig. 4Examples of non-pathological intimal lesions in left anterior descending artery (LAD) and abdominal aorta. Movat’s pentachrome staining. Scale bar 500 µm. a LAD, lean control animal (CD). b LAD, high-fat/high-cholesterol fed animal (HFD); xanthoma with proteoglycan-rich matrix (arrow). c Aorta, CD. d Aorta, HFD; xanthoma
Fig. 5Examples of progressed atherosclerotic lesions in left anterior descending artery (LAD) and abdominal aorta. Movat’s pentachrome staining. Scale bar 500 µm. a LAD, high-fat/high-cholesterol fed animal (HFD), pathological intimal thickening. Inset cholesterol clefts and calcification. b LAD, HFD, fibroatheroma with marked calcification. Inset cap of the lesion. c Pathological intimal thickening in aorta. Inset area of calcification. d Fibroatheroma in aorta. Inset cholesterol clefts disrupted internal elastic lamina and angiogenesis
Fig. 6Distribution of intimal lesions in left anterior descending artery (LAD) (a) and aorta (b) from control (CD), high-fat/high-cholesterol fed (HFD) and high-fat/high-cholesterol fed diabetic animals, group A or B (HFD-DA or B), diet-week 43
Study duration effect on LAD lesion severity in high-fat/high-cholesterol fed animals (HFD) at diet-week 22 (n = 6) and 43 (n = 5)
| Diet week | Non-atherosclerotic intimal lesions | Progressive atherosclerotic lesions | N total |
|---|---|---|---|
| 22 | 5 | 1 | 6 |
| 43 | 1 | 4 | 5 |
| Total | 6 | 5 |
Graduation of lesions according to Virmani et al. [27]. No statistical significant difference was observed in Fisher’s exact test (significance level p < 0.05)
LAD left anterior descending artery, HFD high-fat/high-cholesterol diet fed animals